Last reviewed · How we verify

Janssen Cilag S.A.S. — Portfolio Competitive Intelligence Brief

Janssen Cilag S.A.S. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Epo-alpha Epo-alpha phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Anemia Working Group Romania · 1 shared drug class
  4. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  5. Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
  6. Barts & The London NHS Trust · 1 shared drug class
  7. Bio Sidus SA · 1 shared drug class
  8. Affymax · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Cilag S.A.S.:

Cite this brief

Drug Landscape (2026). Janssen Cilag S.A.S. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-s-a-s. Accessed 2026-05-17.

Related